{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:22Z","timestamp":1787024662912,"version":"build-2736575974"},"reference-count":167,"publisher":"Bentham Science Publishers Ltd.","issue":"24","funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["63454"],"award-info":[{"award-number":["63454"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>The mean global lifetime risk of neurological disorders such as stroke, Alzheimer\u2019s disease (AD),\nand Parkinson\u2019s disease (PD) has shown a large effect on economy and society. Researchers are still struggling\nto find effective drugs to treat neurological disorders and drug delivery through the blood-brain barrier (BBB) is\na major challenge to be overcome. The BBB is a specialized multicellular barrier between peripheral blood circulation\nand neural tissue. Unique and selective features of the BBB allow it to tightly control brain homeostasis\nas well as the movement of ions and molecules. Failure in maintaining any of these substances causes BBB\nbreakdown and subsequently enhances neuroinflammation and neurodegeneration. BBB disruption is evident in\nmany neurological conditions. Nevertheless, the majority of currently available therapies have tremendous\nproblems with drug delivery into the impaired brain. Nanoparticle (NP)-mediated drug delivery has been considered\na profound substitute to solve this problem. NPs are colloidal systems with a size range of 1-1000 nm\nwhich can encapsulate therapeutic payloads, improve drug passage across the BBB, and target specific brain\nareas in neurodegenerative\/ischemic diseases. A wide variety of NPs has been displayed for the efficient brain\ndelivery of therapeutics via intravenous administration, especially when their surfaces are coated with targeting\nmoieties. Here, we discuss recent advances in the development of NP-based therapeutics for the treatment of\nstroke, PD, and AD, as well as the factors affecting their efficacy after systemic administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1381612828666220608093639","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T01:17:32Z","timestamp":1654737452000},"page":"1985-2000","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke\nand Age-related Neurodegenerative Diseases"],"prefix":"10.2174","volume":"28","author":[{"given":"Mehdi","family":"Farhoudi","sequence":"first","affiliation":[{"name":"Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sadigh-Eteghad","sequence":"additional","affiliation":[{"name":"Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Farjami","sequence":"additional","affiliation":[{"name":"Food and Drug Safety Research\nCenter, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Pharmaceutical Analysis Research Center, Tabriz University of\nMedical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mahmoudian","sequence":"additional","affiliation":[{"name":"Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Salatin","sequence":"additional","affiliation":[{"name":"Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41577-020-00474-y","volume":"21","author":"Harschnitz O.","year":"2021","unstructured":"Harschnitz O.; Studer L.; Human stem cell models to study host-virus interactions in the central nervous system. Nat Rev Immunol 2021,21(7),441-453","journal-title":"Nat Rev Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3324\/haematol.2019.241208","volume":"106","author":"Bobillo S.","year":"2021","unstructured":"Bobillo S.; Crespo M.; Escudero L.; Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica 2021,106(2),513-521","journal-title":"Haematologica"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140966","volume":"131","author":"Propson N.E.","year":"2021","unstructured":"Propson N.E.; Roy E.R.; Litvinchuk A.; K\u00f6hl J.; Zheng H.; Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest 2021,131(1)","journal-title":"J Clin Invest"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2020.123563","volume":"402","author":"Wang Z.","year":"2021","unstructured":"Wang Z.; Zhang C.; Huang F.; Liu X.; Wang Z.; Yan B.; Breakthrough of ZrO nanoparticles into fetal brains depends on developmental stage of maternal placental barrier and fetal blood-brain-barrier. J Hazard Mater 2021,402","journal-title":"J Hazard Mater"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669638","volume":"12","author":"K\u00fcpeli Akkol E.","year":"2021","unstructured":"K\u00fcpeli Akkol E.; Tatl\u0131 \u00c7ankaya I.; \u015eeker Karatoprak G.; Carpar E.; Sobarzo-S\u00e1nchez E.; Capasso R.; Natural compounds as medical strategies in the prevention and treatment of psychiatric disorders seen in neurological diseases. Front Pharmacol 2021,12","journal-title":"Front Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trac.2019.05.004","volume":"116","author":"Eftekhari A.","year":"2019","unstructured":"Eftekhari A.; Ahmadian E.; Salatin S.; Current analytical approaches in diagnosis of melanoma. Trends Analyt Chem 2019,116,122-135","journal-title":"Trends Analyt Chem"},{"key":"ref=7","first-page":"65","volume":"1","author":"Salatin S.","year":"2018","unstructured":"Salatin S.; Nanoparticles as potential tools for improved antioxidant enzyme delivery. J Adv Chem Pharm Mater 2018,1(3),65-66","journal-title":"J Adv Chem Pharm Mater"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1039\/D0BM01536A","volume":"9","author":"Zhang H.","year":"2021","unstructured":"Zhang H.; van Os W.L.; Tian X.; Development of curcumin-loaded zein nanoparticles for transport across the blood-brain barrier and inhibition of glioblastoma cell growth. Biomater Sci 2021,9(21),7092-7103","journal-title":"Biomater Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1039\/D1NR02015C","volume":"13","author":"Hou W.","year":"2021","unstructured":"Hou W.; Jiang Y.; Xie G.; \n\n\n Nanoscale 2021,13(18),8531-8542","journal-title":"Nanoscale"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1152\/jn.00638.2020","volume":"125","author":"Figueroa E.G.","year":"2021","unstructured":"Figueroa E.G.; Gonz\u00e1lez-Candia A.; Caballero-Rom\u00e1n A.; Blood-brain barrier dysfunction in hemorrhagic transformation: A therapeutic opportunity for nanoparticles and melatonin. J Neurophysiol 2021,125(6),2025-2033","journal-title":"J Neurophysiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.15171\/apb.2020.003","volume":"10","author":"Salatin S.","year":"2020","unstructured":"Salatin S.; Barar J.; Barzegar-Jalali M.; Adibkia K.; Alami-Milani M.; Jelvehgari M.; \n\n\n\n Adv Pharm Bull 2020,10(1),20-29","journal-title":"Adv Pharm Bull"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2045-8118-9-23","volume":"9","author":"Luissint A-C.","year":"2012","unstructured":"Luissint A-C.; Artus C.; Glacial F.; Ganeshamoorthy K.; Couraud P-O.; Tight junctions at the blood brain barrier: Physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 2012,9(1),23","journal-title":"Fluids Barriers CNS"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101165","volume":"53","author":"Zamanlu M.","year":"2019","unstructured":"Zamanlu M.; Eskandani M.; Barar J.; Jaymand M.; Pakchin P.S.; Farhoudi M.; Enhanced thrombolysis using tissue plasminogen activator (tPA)-loaded PEGylated PLGA nanoparticles for ischemic stroke. J Drug Deliv Sci Technol 2019,53","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/nnm.16.15","volume":"11","author":"Posadas I.","year":"2016","unstructured":"Posadas I.; Monteagudo S.; Ce\u00f1a V.; Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. Nanomedicine (Lond) 2016,11(7),833-849","journal-title":"Nanomedicine (Lond)"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100184","volume":"2","author":"de Gooijer M.C.","year":"2021","unstructured":"de Gooijer M.C.; Kemper E.M.; Buil L.C.M.; ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Rep Med 2021,2(1)","journal-title":"Cell Rep Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41598-020-80889-8","volume":"11","author":"Elabi O.","year":"2021","unstructured":"Elabi O.; Gaceb A.; Carlsson R.; Human \u03b1-synuclein overexpression in a mouse model of Parkinson\u2019s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation. Sci Rep 2021,11(1),1120","journal-title":"Sci Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.stem.2008.07.025","volume":"3","author":"Tavazoie M.","year":"2008","unstructured":"Tavazoie M.; Van der Veken L.; Silva-Vargas V.; A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008,3(3),279-288","journal-title":"Cell Stem Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12035-020-02134-7","volume":"58","author":"Alquisiras-Burgos I.","year":"2021","unstructured":"Alquisiras-Burgos I.; Peralta-Arrieta I.; Alonso-Palomares L.A.; Zacapala-G\u00f3mez A.E.; Salmer\u00f3n-B\u00e1rcenas E.G.; Aguilera P.; Neurological complications associated with the blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection. Mol Neurobiol 2021,58(2),520-535","journal-title":"Mol Neurobiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.15171\/PS.2016.25","volume":"22","author":"Maghsoodi M.","year":"2016","unstructured":"Maghsoodi M.; Rahmani M.; Ghavimi H.; \n\n\n Ulum-i Daruyi 2016,22(3),153-163","journal-title":"Ulum-i Daruyi"},{"key":"ref=20","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.605398","volume":"11","author":"Nian K.","year":"2020","unstructured":"Nian K.; Harding I.C.; Herman I.M.; Ebong E.E.; Blood-brain barrier damage in ischemic stroke and its regulation by endothelial mechanotransduction. Front Physiol 2020,11","journal-title":"Front Physiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-019-0179-3","volume":"9","author":"Zhang Z.","year":"2020","unstructured":"Zhang Z.; Tian Y.; Ye K.; \u03b4-secretase in neurodegenerative diseases: Mechanisms, regulators and therapeutic opportunities. Transl Neurodegener 2020,9(1),1-9","journal-title":"Transl Neurodegener"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.5812\/jjnpp.12873","volume":"13","author":"Salatin S.","year":"2018","unstructured":"Salatin S.; Barar J.; Barzegar-Jalali M.; Adibkia K.; Kiafar F.; Jelvehgari M.; An alternative approach for improved entrapment efficiency of hydrophilic drug substance in PLGA nanoparticles by interfacial polymer deposition following solvent displacement. Jundishapur J Nat Pharm Prod 2018,13(4)","journal-title":"Jundishapur J Nat Pharm Prod"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/10837450.2019.1578370","volume":"24","author":"Alami-Milani M.","year":"2019","unstructured":"Alami-Milani M.; Zakeri-Milani P.; Valizadeh H.; Sattari S.; Salatin S.; Jelvehgari M.; Evaluation of anti-inflammatory impact of dexamethasone-loaded PCL-PEG-PCL micelles on endotoxin-induced uveitis in rabbits. Pharm Dev Technol 2019,24(6),680-688","journal-title":"Pharm Dev Technol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano10091700","volume":"10","author":"Siddique S.","year":"2020","unstructured":"Siddique S.; Chow J.C.L.; Application of nanomaterials in biomedical imaging and cancer therapy. Nanomaterials (Basel) 2020,10(9),1-40","journal-title":"Nanomaterials (Basel)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/17425247.2020.1693998","volume":"16","author":"Salatin S.","year":"2019","unstructured":"Salatin S.; Lotfipour F.; Jelvehgari M.; A brief overview on nano-sized materials used in the topical treatment of skin and soft tissue bacterial infections. Expert Opin Drug Deliv 2019,16(12),1313-1331","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3762\/bjnano.11.25","volume":"11","author":"Francia V.","year":"2020","unstructured":"Francia V.; Montizaan D.; Salvati A.; Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine. Beilstein J Nanotechnol 2020,11(1),338-353","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.33263\/BRIAC92.849852","volume":"9","author":"Sharifi S.","year":"2019","unstructured":"Sharifi S.; Samani A.; Ahmadian E.; Oral delivery of proteins and peptides by mucoadhesive nanoparticles. Biointerface Res Appl Chem 2019,9(2),3849-3852","journal-title":"Biointerface Res Appl Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.biomaterials.2011.11.018","volume":"33","author":"Xin H.","year":"2012","unstructured":"Xin H.; Sha X.; Jiang X.; The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles. Biomaterials 2012,33(5),1673-1681","journal-title":"Biomaterials"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12111013","volume":"12","author":"Caprifico A.E.","year":"2020","unstructured":"Caprifico A.E.; Foot P.J.S.; Polycarpou E.; Calabrese G.; Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers. Pharmaceutics 2020,12(11),1-20","journal-title":"Pharmaceutics"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1063\/1.5027118","volume":"12","author":"Hajal C.","year":"2018","unstructured":"Hajal C.; Campisi M.; Mattu C.; Chiono V.; Kamm R.D.; \n\n\n Biomicrofluidics 2018,12(4)","journal-title":"Biomicrofluidics"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226302","volume":"14","author":"Bernard-Patrzynski F.","year":"2019","unstructured":"Bernard-Patrzynski F.; L\u00e9cuyer M-A.; Puscas I.; Isolation of endothelial cells, pericytes and astrocytes from mouse brain. PLoS One 2019,14(12)","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2009.03.002","volume":"137","author":"Zensi A.","year":"2009","unstructured":"Zensi A.; Begley D.; Pontikis C.; Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009,137(1),78-86","journal-title":"J Control Release"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ejpb.2008.05.007","volume":"70","author":"Reimold I.","year":"2008","unstructured":"Reimold I.; Domke D.; Bender J.; Seyfried C.A.; Radunz H-E.; Fricker G.; Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm 2008,70(2),627-632","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.3171\/2011.10.FOCUS11252","volume":"32","author":"Etame A.B.","year":"2012","unstructured":"Etame A.B.; Diaz R.J.; Smith C.A.; Mainprize T.G.; Hynynen K.; Rutka J.T.; Focused ultrasound disruption of the blood-brain barrier: A new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus 2012,32(1)","journal-title":"Neurosurg Focus"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003937","volume":"8","author":"Zhang W.","year":"2021","unstructured":"Zhang W.; Mehta A.; Tong Z.; Esser L.; Voelcker N.H.; Development of polymeric nanoparticles for blood-brain barrier transfer-strategies and challenges. Adv Sci (Weinh) 2021,8(10)","journal-title":"Adv Sci (Weinh)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1080\/03639045.2020.1788068","volume":"46","author":"Salatin S.","year":"2020","unstructured":"Salatin S.; Jelvehgari M.; Desirability function approach for development of a thermosensitive and bioadhesive nanotransfersome-hydrogel hybrid system for enhanced skin bioavailability and antibacterial activity of cephalexin. Drug Dev Ind Pharm 2020,46(8),1318-1333","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.1038\/s41598-019-45137-8","volume":"9","author":"Iachetta G.","year":"2019","unstructured":"Iachetta G.; Falanga A.; Molino Y.; gH625-liposomes as tool for pituitary adenylate cyclase-activating polypeptide brain delivery. Sci Rep 2019,9(1),9183","journal-title":"Sci Rep"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd6889","volume":"7","author":"Li W.","year":"2021","unstructured":"Li W.; Qiu J.; Li X-L.; BBB pathophysiology-independent delivery of siRNA in traumatic brain injury. Sci Adv 2021,7(1)","journal-title":"Sci Adv"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1021\/acsbiomaterials.0c00743","volume":"6","author":"Brown T.D.","year":"2020","unstructured":"Brown T.D.; Habibi N.; Wu D.; Lahann J.; Mitragotri S.; Effect of nanoparticle composition, size, shape, and stiffness on penetration across the blood-brain barrier. ACS Biomater Sci Eng 2020,6(9),4916-4928","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"22054","DOI":"10.1039\/C9NR02866H","volume":"11","author":"Gonzalez-Carter D.","year":"2019","unstructured":"Gonzalez-Carter D.; Goode A.E.; Kiryushko D.; Quantification of blood-brain barrier transport and neuronal toxicity of unlabelled multiwalled carbon nanotubes as a function of surface charge. Nanoscale 2019,11(45),22054-22069","journal-title":"Nanoscale"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jddst.2015.07.007","volume":"32","author":"Tosi G.","year":"2016","unstructured":"Tosi G.; Musumeci T.; Ruozi B.; The \u201cfate\u201d of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood\u2013brain barrier crossing and trafficking into the central nervous system. J Drug Deliv Sci Technol 2016,32,66-76","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"30201","DOI":"10.1021\/acsami.8b11782","volume":"10","author":"Liang J.","year":"2018","unstructured":"Liang J.; Gao C.; Zhu Y.; Natural brain penetration enhancer-modified albumin nanoparticles for glioma targeting delivery. ACS Appl Mater Interfaces 2018,10(36),30201-30213","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.18433\/jpps30456","volume":"22","author":"Dizaj S.M.","year":"2019","unstructured":"Dizaj S.M.; Rad A.A.; Safaei N.; The application of nanomaterials in cardiovascular diseases: A review on drugs and devices. J Pharm Pharm Sci 2019,22,501-515","journal-title":"J Pharm Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.2147\/IJN.S215941","volume":"14","author":"Dos Santos Rodrigues B.","year":"2019","unstructured":"Dos Santos Rodrigues B.; Lakkadwala S.; Kanekiyo T.; Singh J.; Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomedicine 2019,14,6497-6517","journal-title":"Int J Nanomedicine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejpb.2020.09.003","volume":"156","author":"Monge M.","year":"2020","unstructured":"Monge M.; Fornaguera C.; Quero C.; Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier. Eur J Pharm Biopharm 2020,156,155-164","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12951-020-0585-9","volume":"18","author":"Holmkvist A.D.","year":"2020","unstructured":"Holmkvist A.D.; Agorelius J.; Forni M.; Nilsson U.J.; Linsmeier C.E.; Schouenborg J.; Local delivery of minocycline-loaded PLGA nanoparticles from gelatin-coated neural implants attenuates acute brain tissue responses in mice. J Nanobiotechnology 2020,18(1),27-35","journal-title":"J Nanobiotechnology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/1735-5362.253365","volume":"14","author":"Lotfipour F.","year":"2019","unstructured":"Lotfipour F.; Alami-Milani M.; Salatin S.; Hadavi A.; Jelvehgari M.; Freeze-thaw-induced cross-linked PVA\/chitosan for oxytetracycline-loaded wound dressing: The experimental design and optimization. Res Pharm Sci 2019,14(2),175-189","journal-title":"Res Pharm Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/03639045.2018.1483387","volume":"44","author":"Salatin S.","year":"2018","unstructured":"Salatin S.; Alami-Milani M.; Daneshgar R.; Jelvehgari M.; Box-Behnken experimental design for preparation and optimization of the intranasal gels of selegiline hydrochloride. Drug Dev Ind Pharm 2018,44(10),1613-1621","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.2174\/0929867321666140716100449","volume":"21","author":"Simk\u00f3 M.","year":"2014","unstructured":"Simk\u00f3 M.; Mattsson M-O.; Interactions between nanosized materials and the brain. Curr Med Chem 2014,21(37),4200-4214","journal-title":"Curr Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"Saraiva C.","year":"2016","unstructured":"Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L.; Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016,235,34-47","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2019.07.026","volume":"309","author":"Da Silva-Candal A.","year":"2019","unstructured":"Da Silva-Candal A.; Brown T.; Krishnan V.; Shape effect in active targeting of nanoparticles to inflamed cerebral endothelium under static and flow conditions. J Control Release 2019,309,94-105","journal-title":"J Control Release"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"10753","DOI":"10.1073\/pnas.1308345110","volume":"110","author":"Kolhar P.","year":"2013","unstructured":"Kolhar P.; Anselmo A.C.; Gupta V.; Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci USA 2013,110(26),10753-10758","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1021\/nn200365a","volume":"5","author":"Huang X.","year":"2011","unstructured":"Huang X.; Li L.; Liu T.; \n\n\n ACS Nano 2011,5(7),5390-5399","journal-title":"ACS Nano"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024374","volume":"6","author":"Arvizo R.R.","year":"2011","unstructured":"Arvizo R.R.; Miranda O.R.; Moyano D.F.; Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.carres.2018.03.001","volume":"461","author":"Jiang Z.","year":"2018","unstructured":"Jiang Z.; Dong X.; Sun Y.; Charge effects of self-assembled chitosan-hyaluronic acid nanoparticles on inhibiting amyloid \u03b2-protein aggregation. Carbohydr Res 2018,461,11-18","journal-title":"Carbohydr Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","volume":"118","author":"Kreuter J.","year":"2007","unstructured":"Kreuter J.; Hekmatara T.; Dreis S.; Vogel T.; Gelperina S.; Langer K.; Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 2007,118(1),54-58","journal-title":"J Control Release"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jconrel.2009.10.014","volume":"141","author":"Decuzzi P.","year":"2010","unstructured":"Decuzzi P.; Godin B.; Tanaka T.; Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010,141(3),320-327","journal-title":"J Control Release"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijpharm.2007.06.023","volume":"344","author":"Jallouli Y.","year":"2007","unstructured":"Jallouli Y.; Paillard A.; Chang J.; Sevin E.; Betbeder D.; \n\n\n\n Int J Pharm 2007,344(1-2),103-109","journal-title":"Int J Pharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2006.10.015","volume":"117","author":"Petri B.","year":"2007","unstructured":"Petri B.; Bootz A.; Khalansky A.; Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 2007,117(1),51-58","journal-title":"J Control Release"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1073\/pnas.0914140107","volume":"107","author":"Choi C.H.J.","year":"2010","unstructured":"Choi C.H.J.; Alabi C.A.; Webster P.; Davis M.E.; Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010,107(3),1235-1240","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037376","volume":"7","author":"Jiang W.","year":"2012","unstructured":"Jiang W.; Xie H.; Ghoorah D.; Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One 2012,7(5)","journal-title":"PLoS One"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081043","volume":"8","author":"Gromnicova R.","year":"2013","unstructured":"Gromnicova R.; Davies H.A.; Sreekanthreddy P.; \n\n\n PLoS One 2013,8(12)","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1073\/pnas.1105351108","volume":"108","author":"Martinez-Veracoechea F.J.","year":"2011","unstructured":"Martinez-Veracoechea F.J.; Frenkel D.; Designing super selectivity in multivalent nano-particle binding. Proc Natl Acad Sci USA 2011,108(27),10963-10968","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.1073\/pnas.1307152110","volume":"110","author":"Wiley D.T.","year":"2013","unstructured":"Wiley D.T.; Webster P.; Gale A.; Davis M.E.; Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA 2013,110(21),8662-8667","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2010.04.007","volume":"146","author":"Doshi N.","year":"2010","unstructured":"Doshi N.; Prabhakarpandian B.; Rea-Ramsey A.; Pant K.; Sundaram S.; Mitragotri S.; Flow and adhesion of drug carriers in blood vessels depend on their shape: A study using model synthetic microvascular networks. J Control Release 2010,146(2),196-200","journal-title":"J Control Release"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"8860","DOI":"10.1038\/s41598-019-45139-6","volume":"9","author":"Gopinath P.M.","year":"2019","unstructured":"Gopinath P.M.; Saranya V.; Vijayakumar S.; Assessment on interactive prospectives of nanoplastics with plasma proteins and the toxicological impacts of virgin, coronated and environmentally released-nanoplastics. Sci Rep 2019,9(1),8860","journal-title":"Sci Rep"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1039\/C8EN01054D","volume":"6","author":"Gorshkov V.","year":"2019","unstructured":"Gorshkov V.; Bubis J.A.; Solovyeva E.M.; Gorshkov M.V.; Kjeldsen F.; Protein corona formed on silver nanoparticles in blood plasma is highly selective and resistant to physicochemical changes of the solution. Environ Sci Nano 2019,6(4),1089-1098","journal-title":"Environ Sci Nano"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41419-019-1870-0","volume":"10","author":"Engelberg S.","year":"2019","unstructured":"Engelberg S.; Netzer E.; Assaraf Y.G.; Livney Y.D.; Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death Dis 2019,10(10),702","journal-title":"Cell Death Dis"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/20\/49\/495101","volume":"20","author":"Lee S-Y.","year":"2009","unstructured":"Lee S-Y.; Ferrari M.; Decuzzi P.; Shaping nano-\/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009,20(49)","journal-title":"Nanotechnology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"S\u00e1nchez-L\u00f3pez E.","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E.; Ettcheto M.; Egea M.A.; \n\n\n J Nanobiotechnology 2018,16(1),32","journal-title":"J Nanobiotechnology"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113265","volume":"186","author":"Ahmadian E.","year":"2020","unstructured":"Ahmadian E.; Samiei M.; Hasanzadeh A.; Monitoring of drug resistance towards reducing the toxicity of pharmaceutical compounds: Past, present and future. J Pharm Biomed Anal 2020,186","journal-title":"J Pharm Biomed Anal"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003594","volume":"4","author":"Nance E.A.","year":"2012","unstructured":"Nance E.A.; Woodworth G.F.; Sailor K.A.; A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 2012,4(149)","journal-title":"Sci Transl Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1039\/C9SC03798E","volume":"11","author":"Cheng J.","year":"2019","unstructured":"Cheng J.; Li D.; Sun M.; Physicochemical-property guided design of a highly sensitive probe to image nitrosative stress in the pathology of stroke. Chem Sci (Camb) 2019,11(1),281-289","journal-title":"Chem Sci (Camb)"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neubiorev.2015.08.020","volume":"67","author":"Gibson C.L.","year":"2016","unstructured":"Gibson C.L.; Attwood L.; The impact of gender on stroke pathology and treatment. Neurosci Biobehav Rev 2016,67,119-124","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/jcbfm.2009.248","volume":"30","author":"Bauer A.T.","year":"2010","unstructured":"Bauer A.T.; B\u00fcrgers H.F.; Rabie T.; Marti H.H.; \n\n\n\n J Cereb Blood Flow Metab 2010,30(4),837-848","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102741","volume":"31","author":"Nichols P.","year":"2021","unstructured":"Nichols P.; Urriola J.; Miller S.; Blood-brain barrier dysfunction significantly correlates with serum matrix metalloproteinase-7 (MMP-7) following traumatic brain injury. Neuroimage Clin 2021,31","journal-title":"Neuroimage Clin"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-016-0377-1","volume":"7","author":"Chen J.","year":"2016","unstructured":"Chen J.; Gu Z.; Wu M.; \n\n\n Stem Cell Res Ther 2016,7(1),1-13","journal-title":"Stem Cell Res Ther"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086407","volume":"9","author":"Jiang S.","year":"2014","unstructured":"Jiang S.; Xia R.; Jiang Y.; Wang L.; Gao F.; Vascular endothelial growth factors enhance the permeability of the mouse blood-brain barrier. PLoS One 2014,9(2)","journal-title":"PLoS One"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000499666","volume":"47","author":"Nadareishvili Z.","year":"2019","unstructured":"Nadareishvili Z.; Simpkins A.N.; Hitomi E.; Reyes D.; Leigh R.; Post-stroke blood-brain barrier disruption and poor functional outcome in patients receiving thrombolytic therapy. Cerebrovasc Dis 2019,47(3-4),135-142","journal-title":"Cerebrovasc Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fncel.2014.00362","volume":"8","author":"da Fonseca A.C.C.","year":"2014","unstructured":"da Fonseca A.C.C.; Matias D.; Garcia C.; The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 2014,8,362","journal-title":"Front Cell Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207600","volume":"21","author":"Dong X.","year":"2020","unstructured":"Dong X.; Gao J.; Su Y.; Wang Z.; Nanomedicine for ischemic stroke. Int J Mol Sci 2020,21(20),1-22","journal-title":"Int J Mol Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/1061186X.2017.1365874","volume":"26","author":"Zamanlu M.","year":"2018","unstructured":"Zamanlu M.; Farhoudi M.; Eskandani M.; Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. J Drug Target 2018,26(2),95-109","journal-title":"J Drug Target"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.15171\/bi.2018.05","volume":"8","author":"Zamanlu M.","year":"2018","unstructured":"Zamanlu M.; Eskandani M.; Mohammadian R.; Entekhabi N.; Rafi M.; Farhoudi M.; Spectrophotometric analysis of thrombolytic activity: SATA assay. Bioimpacts 2018,8(1),31-38","journal-title":"Bioimpacts"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/0975-1483.100027","volume":"4","author":"Azam F.","year":"2012","unstructured":"Azam F.; Madi A.M.; Ali H.I.; Molecular docking and prediction of pharmacokinetic properties of dual mechanism drugs that block MAO-B and Adenosine A(2A) receptors for the treatment of Parkinson\u2019s disease. J Young Pharm 2012,4(3),184-192","journal-title":"J Young Pharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/nnano.2014.274","volume":"9","author":"Gaudin A.","year":"2014","unstructured":"Gaudin A.; Yemisci M.; Eroglu H.; Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 2014,9(12),1054-1062","journal-title":"Nat Nanotechnol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1248\/bpb.b18-00683","volume":"42","author":"Fukuta T.","year":"2019","unstructured":"Fukuta T.; Ishii T.; Asai T.; Oku N.; Applications of liposomal drug delivery systems to develop neuroprotective agents for the treatment of ischemic stroke. Biol Pharm Bull 2019,42(3),319-326","journal-title":"Biol Pharm Bull"},{"key":"ref=87","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007197","volume":"7","author":"Wang J.","year":"2018","unstructured":"Wang J.; Zhang Y.; Xia J.; Neuronal PirB upregulated in cerebral ischemia acts as an attractive theranostic target for ischemic stroke. J Am Heart Assoc 2018,7(3)","journal-title":"J Am Heart Assoc"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.lfs.2017.11.046","volume":"193","author":"Hassanzadeh P.","year":"2018","unstructured":"Hassanzadeh P.; Arbabi E.; Atyabi F.; Dinarvand R.; Ferulic acid-loaded nanostructured lipid carriers: A promising nanoformulation against the ischemic neural injuries. Life Sci 2018,193,64-76","journal-title":"Life Sci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"13761","DOI":"10.1523\/JNEUROSCI.4246-09.2009","volume":"29","author":"Karatas H.","year":"2009","unstructured":"Karatas H.; Aktas Y.; Gursoy-Ozdemir Y.; A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009,29(44),13761-13769","journal-title":"J Neurosci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1046\/j.1471-4159.2001.00222.x","volume":"76","author":"Zhang Y.","year":"2001","unstructured":"Zhang Y.; Pardridge W.M.; Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem 2001,76(5),1597-1600","journal-title":"J Neurochem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/jcbfm.2014.220","volume":"35","author":"Yemisci M.","year":"2015","unstructured":"Yemisci M.; Caban S.; Gursoy-Ozdemir Y.; Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab 2015,35(3),469-475","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201902011","volume":"15","author":"Ma J.","year":"2019","unstructured":"Ma J.; Zhang S.; Liu J.; \n\n\n Small 2019,15(35)","journal-title":"Small"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.nano.2016.03.005","volume":"12","author":"Han L.","year":"2016","unstructured":"Han L.; Cai Q.; Tian D.; \n\n\n Nanomedicine (Lond) 2016,12(7),1833-1842","journal-title":"Nanomedicine (Lond)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7150\/thno.18219","volume":"7","author":"Jin Q.","year":"2017","unstructured":"Jin Q.; Cai Y.; Li S.; Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability. Theranostics 2017,7(4),884-898","journal-title":"Theranostics"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.pharmthera.2007.09.008","volume":"117","author":"Han J.Y.","year":"2008","unstructured":"Han J.Y.; Fan J.Y.; Horie Y.; Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008,117(2),280-295","journal-title":"Pharmacol Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1016\/j.biomaterials.2013.05.021","volume":"34","author":"Liu X.","year":"2013","unstructured":"Liu X.; Ye M.; An C.; Pan L.; Ji L.; The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia. Biomaterials 2013,34(28),6893-6905","journal-title":"Biomaterials"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/S0102-865020160020000008","volume":"31","author":"Reyhani-Rad S.","year":"2016","unstructured":"Reyhani-Rad S.; Mahmoudi J.; Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. Acta Cir Bras 2016,31(2),133-137","journal-title":"Acta Cir Bras"},{"key":"ref=98","first-page":"63","volume":"15","author":"Shaafi S.","year":"2016","unstructured":"Shaafi S.; Najmi S.; Aliasgharpour H.; The efficacy of the ketogenic diet on motor functions in Parkinson\u2019s disease: A rat model. Iran J Neurol 2016,15(2),63-69","journal-title":"Iran J Neurol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"Kouli A.","year":"2020","unstructured":"Kouli A.; Camacho M.; Allinson K.; Williams-Gray C.H.; Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. Acta Neuropathol Commun 2020,8(1),211","journal-title":"Acta Neuropathol Commun"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.20369","volume":"57","author":"Kortekaas R.","year":"2005","unstructured":"Kortekaas R.; Leenders K.L.; van Oostrom J.C.; \n\n\n Ann Neurol 2005,57(2),176-179","journal-title":"Ann Neurol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/7854_2014_317","volume":"22","author":"Schneider S.A.","year":"2015","unstructured":"Schneider S.A.; Obeso J.A.; Clinical and pathological features of Parkinson\u2019s disease. Curr Top Behav Neurosci 2015,22,205-220","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","volume":"35","author":"Gray M.T.","year":"2015","unstructured":"Gray M.T.; Woulfe J.M.; Striatal blood-brain barrier permeability in Parkinson\u2019s disease. J Cereb Blood Flow Metab 2015,35(5),747-750","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/j.1471-4159.2007.04567.x","volume":"101","author":"Rite I.","year":"2007","unstructured":"Rite I.; Machado A.; Cano J.; Venero J.L.; \n\n\n\n J Neurochem 2007,101(6),1567-1582","journal-title":"J Neurochem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00702-004-0256-2","volume":"112","author":"Barcia C.","year":"2005","unstructured":"Barcia C.; Bautista V.; S\u00e1nchez-Bahillo A.; Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm (Vienna) 2005,112(9),1237-1248","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/370526","volume":"2013","author":"Chung Y.C.","year":"2013","unstructured":"Chung Y.C.; Kim Y-S.; Bok E.; Yune T.Y.; Maeng S.; Jin B.K.; MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson\u2019s disease. Mediators Inflamm 2013,2013","journal-title":"Mediators Inflamm"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00702-011-0684-8","volume":"119","author":"Desai Bradaric B.","year":"2012","unstructured":"Desai Bradaric B.; Patel A.; Schneider J.A.; Carvey P.M.; Hendey B.; Evidence for angiogenesis in Parkinson\u2019s disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna) 2012,119(1),59-71","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/brain\/awr298","volume":"135","author":"van Assema D.M.","year":"2012","unstructured":"van Assema D.M.; Lubberink M.; Bauer M.; Blood-brain barrier P-glycoprotein function in Alzheimer\u2019s disease. Brain 2012,135(Pt 1),181-189","journal-title":"Brain"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neulet.2013.06.058","volume":"551","author":"Jangula A.","year":"2013","unstructured":"Jangula A.; Murphy E.J.; Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression. Neurosci Lett 2013,551,23-27","journal-title":"Neurosci Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/JAD-2006-102-309","volume":"10","author":"Yokel R.A.","year":"2006","unstructured":"Yokel R.A.; Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 2006,10(2-3),223-253","journal-title":"J Alzheimers Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s004010050468","volume":"91","author":"Leveugle B.","year":"1996","unstructured":"Leveugle B.; Faucheux B.A.; Bouras C.; Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson\u2019s disease cases. Acta Neuropathol 1996,91(6),566-572","journal-title":"Acta Neuropathol"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009258","volume":"2","author":"Dickson D.W.","year":"2012","unstructured":"Dickson D.W.; Parkinson\u2019s disease and parkinsonism: Neuropathology. Cold Spring Harb Perspect Med 2012,2(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=112","first-page":"1599","volume":"7","author":"Wen C-J.","year":"2012","unstructured":"Wen C-J.; Zhang L-W.; Al-Suwayeh S.A.; Yen T-C.; Fang J-Y.; Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine 2012,7,1599-1611","journal-title":"Int J Nanomedicine"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1515\/revneuro-2017-0040","volume":"29","author":"Nasrolahi A.","year":"2018","unstructured":"Nasrolahi A.; Mahmoudi J.; Akbarzadeh A.; Neurotrophic factors hold promise for the future of Parkinson\u2019s disease treatment: Is there a light at the end of the tunnel? Rev Neurosci 2018,29(5),475-489","journal-title":"Rev Neurosci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","volume":"277","author":"Qu M.","year":"2018","unstructured":"Qu M.; Lin Q.; He S.; A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease. J Control Release 2018,277,173-182","journal-title":"J Control Release"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.actbio.2020.03.021","volume":"109","author":"Vong L.B.","year":"2020","unstructured":"Vong L.B.; Sato Y.; Chonpathompikunlert P.; Tanasawet S.; Hutamekalin P.; Nagasaki Y.; Self-assembled polydopamine nanoparticles improve treatment in Parkinson\u2019s disease model mice and suppress dopamine-induced dyskinesia. Acta Biomater 2020,109,220-228","journal-title":"Acta Biomater"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jddst.2018.08.016","volume":"48","author":"Ray S.","year":"2018","unstructured":"Ray S.; Sinha P.; Laha B.; Maiti S.; Bhattacharyya U.K.; Nayak A.K.; Polysorbate 80 coated crosslinked chitosan nanoparticles of ropinirole hydrochloride for brain targeting. J Drug Deliv Sci Technol 2018,48,21-29","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1021\/nn506408v","volume":"9","author":"Pahuja R.","year":"2015","unstructured":"Pahuja R.; Seth K.; Shukla A.; Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 2015,9(5),4850-4871","journal-title":"ACS Nano"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","volume":"415","author":"Hu K.","year":"2011","unstructured":"Hu K.; Shi Y.; Jiang W.; Han J.; Huang S.; Jiang X.; Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson\u2019s disease. Int J Pharm 2011,415(1-2),273-283","journal-title":"Int J Pharm"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"21730","DOI":"10.1021\/jacs.0c09390","volume":"142","author":"Liu H.","year":"2020","unstructured":"Liu H.; Han Y.; Wang T.; Targeting microglia for therapy of Parkinson\u2019s Disease by using biomimetic ultrasmall nanoparticles. J Am Chem Soc 2020,142(52),21730-21742","journal-title":"J Am Chem Soc"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101090","volume":"21","author":"Xu S-F.","year":"2019","unstructured":"Xu S-F.; Zhang Y-H.; Wang S.; Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice. Redox Biol 2019,21","journal-title":"Redox Biol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1166\/jbn.2012.1462","volume":"8","author":"Lalani J.","year":"2012","unstructured":"Lalani J.; Raichandani Y.; Mathur R.; Comparative receptor based brain delivery of tramadol-loaded poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol 2012,8(6),918-927","journal-title":"J Biomed Nanotechnol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jgm.1361","volume":"11","author":"Huang R.","year":"2009","unstructured":"Huang R.; Han L.; Li J.; Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 2009,11(9),754-763","journal-title":"J Gene Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2009.09.032","volume":"290","author":"Huang R.","year":"2010","unstructured":"Huang R.; Ke W.; Liu Y.; Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 2010,290(1-2),123-130","journal-title":"J Neurol Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/10611860903112842","volume":"17","author":"Kurakhmaeva K.B.","year":"2009","unstructured":"Kurakhmaeva K.B.; Djindjikhashvili I.A.; Petrov V.E.; Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009,17(8),564-574","journal-title":"J Drug Target"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1039\/c2nr30346a","volume":"4","author":"Wang L.","year":"2012","unstructured":"Wang L.; Zhang L.; Xue X.; Ge G.; Liang X.; Enhanced dispersibility and cellular transmembrane capability of single-wall carbon nanotubes by polycyclic organic compounds as chaperon. Nanoscale 2012,4(13),3983-3989","journal-title":"Nanoscale"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1021\/nl061241t","volume":"6","author":"Wang K.","year":"2006","unstructured":"Wang K.; Fishman H.A.; Dai H.; Harris J.S.; Neural stimulation with a carbon nanotube microelectrode array. Nano Lett 2006,6(9),2043-2048","journal-title":"Nano Lett"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"7615","DOI":"10.2147\/IJN.S276380","volume":"15","author":"Kim O-H.","year":"2020","unstructured":"Kim O-H.; Park J.H.; Son J.I.; Kim K-Y.; Lee H.J.; Both intracranial and intravenous administration of functionalized carbon nanotubes protect dopaminergic neuronal death from 6-hydroxydopamine. Int J Nanomedicine 2020,15,7615-7626","journal-title":"Int J Nanomedicine"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"Guo T.","year":"2020","unstructured":"Guo T.; Zhang D.; Zeng Y.; Huang T.Y.; Xu H.; Zhao Y.; Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener 2020,15(1),40","journal-title":"Mol Neurodegener"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Cheng Y.","year":"2020","unstructured":"Cheng Y.; Tian D-Y.; Wang Y-J.; Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: Pathophysiology and therapeutic perspectives. Transl Neurodegener 2020,9(1),16","journal-title":"Transl Neurodegener"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fncel.2015.00065","volume":"9","author":"Canobbio I.","year":"2015","unstructured":"Canobbio I.; Abubaker A.A.; Visconte C.; Torti M.; Pula G.; Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer\u2019s disease. Front Cell Neurosci 2015,9,65","journal-title":"Front Cell Neurosci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","volume":"140","author":"Kent S.A.","year":"2020","unstructured":"Kent S.A.; Spires-Jones T.L.; Durrant C.S.; The physiological roles of tau and A\u03b2: Implications for Alzheimer\u2019s disease pathology and therapeutics. Acta Neuropathol 2020,140(4),417-447","journal-title":"Acta Neuropathol"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.695479","volume":"15","author":"Wang D.","year":"2021","unstructured":"Wang D.; Chen F.; Han Z.; Yin Z.; Ge X.; Lei P.; Relationship between amyloid-\u03b2 deposition and blood-brain barrier dysfunction in Alzheimer\u2019s disease. Front Cell Neurosci 2021,15","journal-title":"Front Cell Neurosci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","volume":"36","author":"Cai Z.","year":"2016","unstructured":"Cai Z.; Liu N.; Wang C.; Role of RAGE in Alzheimer\u2019s disease. Cell Mol Neurobiol 2016,36(4),483-495","journal-title":"Cell Mol Neurobiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2174\/18715273113129990072","volume":"12","author":"Sochocka M.","year":"2013","unstructured":"Sochocka M.; Koutsouraki E.S.; Gasiorowski K.; Leszek J.; Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer\u2019s disease: A new approach to therapy. CNS Neurol Disord Drug Targets 2013,12(6),870-881","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13195-020-00712-4","volume":"12","author":"Emrani S.","year":"2020","unstructured":"Emrani S.; Arain H.A.; DeMarshall C.; Nuriel T.; APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer\u2019s disease: A systematic review. Alzheimers Res Ther 2020,12(1),141-150","journal-title":"Alzheimers Res Ther"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"Shibata M.","year":"2000","unstructured":"Shibata M.; Yamada S.; Kumar S.R.; Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000,106(12),1489-1499","journal-title":"J Clin Invest"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12974-021-02117-y","volume":"18","author":"Davis N.","year":"2021","unstructured":"Davis N.; Mota B.C.; Stead L.; Pharmacological ablation of astrocytes reduces A\u03b2 degradation and synaptic connectivity in an ex vivo model of Alzheimer\u2019s disease. J Neuroinflammation 2021,18(1),73","journal-title":"J Neuroinflammation"},{"key":"ref=138","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4626540","volume":"2017","author":"Mietelska-Porowska A.","year":"2017","unstructured":"Mietelska-Porowska A.; Wojda U.; T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer\u2019s disease: Potential pools of new biomarkers. J Immunol Res 2017,2017","journal-title":"J Immunol Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5715","volume":"2","author":"Iadecola C.","year":"1999","unstructured":"Iadecola C.; Zhang F.; Niwa K.; SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 1999,2(2),157-161","journal-title":"Nat Neurosci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.20493","volume":"57","author":"Ruitenberg A.","year":"2005","unstructured":"Ruitenberg A.; den Heijer T.; Bakker S.L.; Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study. Ann Neurol 2005,57(6),789-794","journal-title":"Ann Neurol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nn.3966","volume":"18","author":"Winkler E.A.","year":"2015","unstructured":"Winkler E.A.; Nishida Y.; Sagare A.P.; GLUT1 reductions exacerbate Alzheimer\u2019s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 2015,18(4),521-530","journal-title":"Nat Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/bph.14581","volume":"176","author":"Reynolds D.S.","year":"2019","unstructured":"Reynolds D.S.; A short perspective on the long road to effective treatments for Alzheimer\u2019s disease. Br J Pharmacol 2019,176(18),3636-3648","journal-title":"Br J Pharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","volume":"176","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; Xu S.; Zhu Z.; Xu J.; Multi-target design strategies for the improved treatment of Alzheimer\u2019s disease. Eur J Med Chem 2019,176,228-247","journal-title":"Eur J Med Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14740338.2020.1721456","volume":"19","author":"Haake A.","year":"2020","unstructured":"Haake A.; Nguyen K.; Friedman L.; Chakkamparambil B.; Grossberg G.T.; An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Saf 2020,19(2),147-157","journal-title":"Expert Opin Drug Saf"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/smll.201201870","volume":"9","author":"Guarnieri D.","year":"2013","unstructured":"Guarnieri D.; Falanga A.; Muscetti O.; Shuttle-mediated nanoparticle delivery to the blood-brain barrier. Small 2013,9(6),853-862","journal-title":"Small"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.colsurfb.2015.06.025","volume":"134","author":"Meng F.","year":"2015","unstructured":"Meng F.; Asghar S.; Gao S.; A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer\u2019s disease. Colloids Surf B Biointerfaces 2015,134,88-97","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=147","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf9180","volume":"7","author":"Duro-Castano A.","year":"2021","unstructured":"Duro-Castano A.; Borr\u00e1s C.; Herranz-P\u00e9rez V.; Targeting Alzheimer\u2019s disease with multimodal polypeptide-based nanoconjugates. Sci Adv 2021,7(13)","journal-title":"Sci Adv"},{"key":"ref=148","first-page":"18","volume":"2","author":"Khemariya R.P.","year":"2016","unstructured":"Khemariya R.P.; Khemariya P.S.; New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation. Int J Curr Res Med Sci 2016,2(2),18-29","journal-title":"Int J Curr Res Med Sci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","volume":"31","author":"Wang Z.H.","year":"2010","unstructured":"Wang Z.H.; Wang Z.Y.; Sun C.S.; Wang C.Y.; Jiang T.Y.; Wang S.L.; Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010,31(5),908-915","journal-title":"Biomaterials"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"81001","DOI":"10.18632\/oncotarget.20944","volume":"8","author":"Huang N.","year":"2017","unstructured":"Huang N.; Lu S.; Liu X-G.; Zhu J.; Wang Y-J.; Liu R-T.; PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A\u03b2 generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer\u2019s disease mice. Oncotarget 2017,8(46),81001-81013","journal-title":"Oncotarget"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-020-00626-1","volume":"18","author":"Gao C.","year":"2020","unstructured":"Gao C.; Chu X.; Gong W.; Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer\u2019s disease. J Nanobiotechnology 2020,18(1),71","journal-title":"J Nanobiotechnology"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/bc400055h","volume":"24","author":"Liu Z.","year":"2013","unstructured":"Liu Z.; Gao X.; Kang T.; B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug Chem 2013,24(6),997-1007","journal-title":"Bioconjug Chem"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801586","volume":"6","author":"Lu Y.","year":"2018","unstructured":"Lu Y.; Guo Z.; Zhang Y.; Microenvironment remodeling micelles for Alzheimer\u2019s disease therapy by early modulation of activated microglia. Adv Sci (Weinh) 2018,6(4)","journal-title":"Adv Sci (Weinh)"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","volume":"14","author":"Carradori D.","year":"2018","unstructured":"Carradori D.; Balducci C.; Re F.; Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model. Nanomedicine (Lond) 2018,14(2),609-618","journal-title":"Nanomedicine (Lond)"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/wnan.59","volume":"2","author":"Kulkarni P.V.","year":"2010","unstructured":"Kulkarni P.V.; Roney C.A.; Antich P.P.; Bonte F.J.; Raghu A.V.; Aminabhavi T.M.; Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer\u2019s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010,2(1),35-47","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"Hou K.","year":"2020","unstructured":"Hou K.; Zhao J.; Wang H.; Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun 2020,11(1),4790","journal-title":"Nat Commun"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1021\/acsbiomaterials.1c00514","volume":"7","author":"Singh A.K.","year":"2021","unstructured":"Singh A.K.; Singh S.S.; Rathore A.S.; Lipid-Coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater Sci Eng 2021,7(8),3737-3753","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1021\/acs.nanolett.9b04018","volume":"20","author":"Wang H.","year":"2020","unstructured":"Wang H.; Xu X.; Guan X.; Liposomal 9-aminoacridine for treatment of ischemic stroke: From drug discovery to drug delivery. Nano Lett 2020,20(3),1542-1551","journal-title":"Nano Lett"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3389\/fphar.2018.01403","volume":"9","author":"Xu H.","year":"2018","unstructured":"Xu H.; Hua Y.; Zhong J.; Resveratrol delivery by albumin nanoparticles improved neurological function and neuronal damage in transient middle cerebral artery occlusion rats. Front Pharmacol 2018,9,1403","journal-title":"Front Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/cells10051011","volume":"10","author":"Dhuri K.","year":"2021","unstructured":"Dhuri K.; Vyas R.N.; Blumenfeld L.; Verma R.; Bahal R.; Nanoparticle delivered anti-miR-141-3p for stroke therapy. Cells 2021,10(5),1011-1020","journal-title":"Cells"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/157341311794653686","volume":"7","author":"Hsu S-H.","year":"2011","unstructured":"Hsu S-H.; Al-Suwayeh S.; Chen C.C.; Chi C-H.; Fang J-Y.; \n\n\n\n Curr Nanosci 2011,7(2),191-199","journal-title":"Curr Nanosci"},{"key":"ref=162","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/21\/40\/405101","volume":"21","author":"Hsu S-H.","year":"2010","unstructured":"Hsu S-H.; Wen C-J.; Al-Suwayeh S.A.; Chang H-W.; Yen T-C.; Fang J-Y.; \n\n\n\n Nanotechnology 2010,21(40)","journal-title":"Nanotechnology"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.7150\/thno.28295","volume":"8","author":"Li Y.","year":"2018","unstructured":"Li Y.; Chen Z.; Lu Z.; \n\n\n Theranostics 2018,8(19),5469-5481","journal-title":"Theranostics"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.S.; Paramakrishnan N.; Suresh B.; Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 2008,1200,159-168","journal-title":"Brain Res"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fphar.2019.00910","volume":"10","author":"Bilia A.R.","year":"2019","unstructured":"Bilia A.R.; Nardiello P.; Piazzini V.; Successful brain delivery of andrographolide loaded in human albumin nanoparticles to TgCRND8 mice, an Alzheimer\u2019s Disease mouse model. Front Pharmacol 2019,10,910","journal-title":"Front Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","volume":"148","author":"Sun D.","year":"2016","unstructured":"Sun D.; Li N.; Zhang W.; Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer\u2019s disease. Colloids Surf B Biointerfaces 2016,148,116-129","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2147\/IJN.S236922","volume":"15","author":"Xu R.","year":"2020","unstructured":"Xu R.; Wang J.; Xu J.; Rhynchophylline Loaded-mPEG-PLGA nanoparticles coated with tween-80 for preliminary study in Alzheimer\u2019s Disease. Int J Nanomedicine 2020,15,1149-1160","journal-title":"Int J Nanomedicine"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220608093639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205708\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220608093639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T13:05:54Z","timestamp":1691672754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205708\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":167,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220608093639","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}